THERAVANCE COMPLETES ENROLLMENT FOR ANTIBIOTIC TRIAL

A A

Theravance has completed enrollment in its first Phase III clinical program with the investigational antibiotic telavancin in patients with complicated skin and skin structure infections due to Gram-positive bacteria. The trial will include patients with resistant strains of disease including methicillin-resistant Staphylococcus aureus (MRSA).

Telavancin inhibits the formation of the bacterial cell wall and disrupts bacterial cell membrane integrity. The company said in a statement that it believes the additive mechanisms of action seen with telavancin speed bacterial killing while also reducing the risks of inducing resistance to telavancin or cross-resistance with other antibiotics.